MPTP-induced model of Parkinson's disease in cytochrome P450 2E1knockout mice

Neuropharmacology

Volumn 56, Issue 8, 2009, Pages 1075-1081

  Viaggi, C ^a   Vaglini, F ^a   Pardini, C ^a   Caramelli, A ^a   Corsini, G U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cyp2e1 knockout mice; Cytochrome P450 2E1 (CYP2E1); Dopamine; MPP+; MPTP; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 O METHYLDOPAMINE; CYTOCHROME P450 2E1; DOPAMINE; HOMOVANILLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE MODEL; DOPAMINE RELEASE; GENETIC DRIFT; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STRAIN DIFFERENCE; SUBSTANTIA NIGRA; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CORPUS STRIATUM; CYTOCHROME P-450 CYP2E1; DOPAMINE; HOMOVANILLIC ACID; MALE; MICE; MICE, KNOCKOUT; MPTP POISONING; NERVE TISSUE PROTEINS; NEURONS; PARKINSONIAN DISORDERS; PRODRUGS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 67349259602     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.03.003     Document Type: Article

References (62)

1. Anandatheerthavarada H.K., Shankar S.K., Bhamre S., Boyd M.R., Song B.J., and Ravindranath V. Induction of brain cytochrome P-450IIE1 by chronic ethanol treatment. Brain Res. 601 (1993) 279-285
2. Anandatheerthavarada H.K., Williams J.F., and Wecker L. Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem. Biophys. Res. Commun 194 (1993) 312-318
3. Bandmann O., Vaughan J., Holmans P., Marsden C.D., and Wood N.W. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350 (1997) 1136-1139
4. Barbeau A., Cloutier T., Roy M., Plasse L., Paris S., and Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 2 (1985) 1213-1216
5. Bocchetta A., Piccardi M.P., Del Zompo M., Pintus S., and Corsini G.U. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro. J. Neurochem 45 (1985) 673-676
6. Brzezinski M.R., Boutelet-Bochan H., Person R.E., Fantel A.G., and Juchau M.R. Catalytic activity and quantitation of cytochrome P-450 2E1 in prenatal human brain. J. Pharmacol. Exp. Ther 289 (1999) 1648-1653
7. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun 120 (1984) 574-578
8. Corsini G.U., Maggio R., and Vaglini F. Molecular and cellular events regulating dopamine neuron survival. In: Di Chiara G. (Ed). Handbook of Experimental Pharmacology. Dopamine in the CNS Vol. 154 (2002), Springer, Berlin 321-386 Part II
9. Cotè S.L., Ribeiro-da-Silva A., and Cuello A.C. Current protocols for light microscopy immunocytochemistry. In: Cuello A.C. (Ed) (1993), Immunohistochemistry II. John Wiley, Chichester 147-168
10. Danko I.M., and Chaschin N.A. Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp. Oncol 27 (2005) 248-256
11. Davis C.G., Williams A.C., Markey S.P., Ebert M.H., Calne E.D., Reichert C.M., and Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 (1979) 249-254
12. de Waziers I., Cugnenc P.H., Yang C.S., Leroux J.P., and Beaune P.H. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther 253 (1990) 387-394
13. Del Zompo M., Piccardi M.P., Ruiu S., Corsini G.U., and Vaccari A. High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. Eur. J. Pharmacol 202 (1991) 293-294
14. Del Zompo M., Piccardi M.P., Ruiu S., Albanese A., and Morelli M. Localization of MPP+ binding sites in the brain of various mammalian species. J. Neural. Transm. Park. Dis. Dement. Sect 4 (1992) 181-190
15. Del Zompo M., Piccardi M.P., Ruiu S., Quartu M., Gessa G.L., and Vaccari A. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br. J. Pharmacol 109 (1993) 411-414
16. Denton T., and Howard B.D. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem 49 (1987) 622-630
17. Di Monte D., Jewell S.A., Ekström G.G., Sandy M.S., and Smith M.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun 137 (1986) 310-315
18. Farin F.M., and Omiecinski C.J. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 40 (1993) 317-335
19. Glowinski J., and Iversen L.L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem 13 (1966) 655-669
20. Gonzalez F.J. The 2006 Bernard B. Brodie Award Lecture. Cyp2E1. Drug Metab. Dispos 35 (2007) 1-8
21. Hanioka N., Tanaka-Kagawa T., Miyata Y., Matsushima E., Makino Y., Ohno A., Yoda R., Jinno H., and Ando M. Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. Xenobiotica 33 (2003) 575-586
22. Hansson T., Tindberg N., Ingelman-Sundberg M., and Köhler C. Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience 34 (1990) 451-463
23. Hu Y., Oscarson M., Johansson I., Yue Q.Y., Dahl M.L., Tabone M., Arinco S., Albano E., and Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol 51 (1997) 370-376
24. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol 369 (2004) 89-104
25. Javitch J.A., and Snyder S.H. Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol 106 (1984) 455-456
26. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82 (1985) 2173
27. Jollow D.J., Mitchell J.R., Potter W.Z., Davis D.C., Gillette J.R., and Brodie B.B. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther 187 (1973) 195-202
28. Jones S.R., Gainetdinov R.R., Wightman R.M., and Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci 18 (1998) 1979-1986
29. Joshi M., and Tyndale R.F. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 50 (2006) 568-575
30. Karuzina I.I., and Archakov A.I. The oxidative inactivation of cytochrome P450 in monooxygenase reactions. Free Radic. Biol. Med 16 (1994) 73-97
31. Kopin I. Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons. In: Herken H., and Hucho F. (Eds). Handbook of Experimental Pharmacology. Selective Neurotoxicity Vol. 102 (1992), Springer, Berlin 333-356
32. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
33. Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., and Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271 (1996) 12063-12067
34. Liang Z., Engrav L.H., Muangman P., Mufey L.A., Zhu K.Q., Carrougher G.J., Underwood R.A., and Gibran N.S. Nerve quantification in female red Duroc pig (FRDP) scar compared to human hypertrophic scar. Burns 30 (2004) 57-64
35. Lieber C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 77 (1997) 517-544
36. Marí M., and Cederbaum A.I. Induction of catalase, alpha, and microsomal glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress. Hepatology 33 (2001) 652-661
37. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., and Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
38. McCarver D.G., Byun R., Hines R.N., Hichme M., and Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol 152 (1998) 276-281
39. Mitchell J.R., Jollow D.J., Potter W.Z., Gillette J.R., and Brodie B.B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther 187 (1973) 211-217
40. Mohanakumar K.P., Thomas B., Sharma S.M., Muralikrishnan D., Chowdhury R., and Chiueh C.C. Nitric oxide: an antioxidant and neuroprotector. Ann. N.Y. Acad. Sci 962 (2002) 389-401
41. Montoliu C., Sancho-Tello M., Azorin I., Burgal M., Vallés S., Renau-Piqueras J., and Guerri C. Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. J. Neurochem 65 (1995) 2561-2570
42. Niazi Shahabi H., Bergquist F., and Nissbrandt H. An investigation of dopaminergic metabolites in the striatum and in the substantia nigra in vivo utilising radiolabelled l-DOPA and high performance liquid chromatography: a new approach in the search for transmitter metabolites. Neuroscience 120 (2003) 425-433
43. Niazi Shahabi H., Andersson D.R., and Nissbrandt H. Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production. Synapse 62 (2008) 379-388
44. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
45. Nissbrandt H., Bergquist F., Jonason J., and Engberg G. Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway?. Synapse 40 (2001) 294-301
46. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. second ed. (2001), Academic Press, Hong Kong
47. Ramsay R.R., and Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 (1986) 7585-7587
48. Riedl A.G., Watts P.M., Edwards R.J., Boobis A.R., Jenner P., and Marsden C.D. Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Res. 743 (1996) 324-328
49. Ronis M.J.J., Lindros K.O., and Ingelman-Sundberg M. The CYP2 Subfamily. In: Ioannides C. (Ed). Cytochromes P450: Metabolic and Toxicological Aspects (1996), CRC Press, Boca Raton
50. Sohda T., Shimizu M., Kamimura S., and Okumura M. Immunohistochemical demonstration of ethanol-inducible P450 2E1 in rat brain. Alcohol Alcohol Suppl. 1B (1993) 69-75
51. Sonsalla P.K., and Nicklas W.J. MPTP and animal models of Parkinson's disease. In: Koller W.C. (Ed). Handbook of Parkinson's Disease. second ed (1992), Marcel Dekker, New York 319-340
52. Staal R.G., and Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther 293 (2000) 336-342
53. Staudt H., Lichtenberger F., and Ullrich V. The role of NADH in uncoupled microsomal monoxygenations. Eur. J. Biochem 46 (1974) 99-106
54. Stern-Bach Y., Keen J.N., Bejerano M., Steiner-Mordoch S., Wallach M., Findlay J.B., and Schuldiner S. Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 89 (1992) 9730-9733
55. Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., and Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord 18 (2003) 121-129
56. Thomas P.E., Bandiera S., Reik L.M., Maines S.L., Ryan D.E., and Levin W. Polyclonal and monoclonal antibodies as probes of rat hepatic cytochrome P-450 isozymes. Fed. Proc. 46 (1987) 2563-2566
57. Tierney D.J., Haas A.L., and Koop D.R. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch. Biochem. Biophys 293 (1992) 9-16
58. Upadhya S.C., Tirumalai P.S., Boyd M.R., Mori T., and Ravindranath V. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch. Biochem. Biophys 373 (2000) 23-34
59. Vaglini F., Pardini C., Viaggi C., Bartoli C., Dinucci D., and Corsini G.U. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. J. Neurochem 91 (2004) 285-298
60. Wang J., Liu Z., and Chan P. Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's disease in a Chinese population. Mov. Disord 15 (2000) 1267-1269
61. Watts P.M., Riedl A.G., Douek D.C., Edwards R.J., Boobis A.R., Jenner P., and Marsden C.D. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86 (1998) 511-519
62. Wu R.M., Cheng C.W., Chen K.H., Shan D.E., Kuo J.W., Ho Y.F., and Chern H.D. Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese. J. Neural Transm 109 (2002) 1403-1414